Clinical trials: Individual Psychiatric Disorder
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Narcolepsy
A Study to Collect Information of People With Narcolepsy in Spain
This study aims to review information of people with a sleep condition called narcolepsy. Narcolepsy is a condition that causes extreme sleepiness during the day including falling asleep suddenly.
- Trial name
- SOMNUS (NCT04667338)
- Where
- Spain
- Volunteers
- 214 people
- Sponsor
- Takeda
Alzheimer's Disease
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
This is a randomized, double-blind, placebo-controlled first-in-human, Phase 1, safety, tolerability, pharmacokinetic (PK) and preliminary exploratory activity study of escalating multiple intravenous (IV) doses of IBC-Ab002 in…
- Trial name
- NCT05551741
- Testing
- IBC-Ab002
- Where
- 10 sites in Israel, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- Immunobrain Checkpoint
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
7-week Study With CT-155 in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) to treat schizophrenia
- Trial name
- NCT05486312
- Testing
- CT-155 smartphone app
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Click Therapeutics, Inc.
Posttraumatic Stress Disorder
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD).
- Trial name
- NCT00090064
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Resilient Pharmaceuticals
Situational Anxiety
Study of the Anxiolytic Effects of Aframomum Seed Extract in Elderly People
The goal of this pilot clinical trial is to evaluate if one specific botanical extract from Grains of Paradise works to induce anxiolytic effect in adult people in stress or anxiety situations It will also learn about the…
- Trial name
- NCT06463145
- Testing
- Vanizem
- Where
- Spain
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Nektium Pharma SL
Migraine Disorders, Headache Disorders
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone
This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone…
- Conditions
- Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases
- Trial name
- Migraine (NCT03762902)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lifegraph Ltd.
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 40 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Sleep Disorder
Accuracy Evaluation of EarlySense With Modified Sensor (Smaller Shape Sensor With BLE) at Home Setting Monitoring a Subject While Partner in Bed
Accuracy evaluation of EarlySense device, a smaller shape sensor with BLE connection to processing unit (HUB)) for use while two people are in bed ("Home Use" scenario) The EarlySense device is intended for continuous…
- Trial name
- NCT05237518
- Testing
- EarlySense Noomi system
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- EarlySense Ltd.
Haemophilia A, Haemophilia B
Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
The puropse of this non-interventional register and survey study is to identify the patterns of prescribed pain, anti-depressive and anti-anxiety medication and management of pain, depression and anxiety for people with…
- Trial name
- MIND (NCT03276130)
- Where
- 5 sites in Denmark, Finland and 1 more
- Volunteers
- 2,300 people
- Sponsor
- Swedish Orphan Biovitrum
Dementia, Alzheimer Disease
All About Me: An Intervention to Ease the Transition to Long Term Care
This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed
- Trial name
- AAM (NCT05516134)
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Hopeful Aging
Cancer, Psycho-Oncology
What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support.
- Trial name
- PICS (NCT07544446)
- Testing
- initial psycho-oncological contact, Standard
- Where
- 5 sites in Switzerland
- Volunteers
- 148 people
- Sponsor
- Lindenhofgruppe AG
Alzheimer's Disease, Parkinson's Disease
Evaluation of a Diet in Patients With Senile Dementia
The most common symptoms associated to senile dementia disease are confusion about schedules, hyperactivity... In this sense, these patients have frequently poor nutrition, resulting in malnutrition problems or malnutrition high…
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Senile Dementia
- Trial name
- SUPRESSI (NCT01192529)
- Testing
- Supressi. T-Diet plus Range, High Protein. T-Diet plus Range
- Where
- 3 sites in Spain
- Volunteers
- 184 people
- Sponsor
- Vegenat, S.A.
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Post Traumatic Stress Disorder
Exploring Clinical Study Experiences of People With Post Traumatic Stress Disorder
Participation in post traumatic stress disorder observational study serves as a crucial contribution to advancing medical knowledge and refining the care provided to individuals facing similar health challenges.
- Trial name
- NCT06146049
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Autism Spectrum Disorder
Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
This is an 18 to 54 week study assessing the efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people.
- Trial name
- NCT05626959
- Testing
- NTI164
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- Fenix Innovation Group
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.